About Us

Established in 2003, we are a leading Israeli Investment Company specializing in the Biotechnology sector and focusing exclusively on highly select opportunities in the life sciences including, therapeutics, diagnostic and agro-bio space. Since 2004, Coronis has invested over $10M in seven high quality portfolio companies. In 2007, four of our companies issued public offerings – BiondVax (TASE: BNDX) and Evogene (TASE: EVGN) in Tel Aviv; Rosetta Genomics (Nasdaq:ROSG) and Modigene (Nasdaq:MODG) at Nasdaq. As of August 2009, Coronis' portfolio valuation has doubled , representing an IRR of more than 30% per year.